-+ 0.00%
-+ 0.00%
-+ 0.00%

CARDIFF ONCOLOGY - ONVANSERTIB SHOWED PRELIMINARY EFFICACY IN 40% OF MYELOPROLIFERATIVE CMML PATIENTS

Reuters·10/21/2026 20:28:48